Rueschoff, Josef, Baretton, Gustavo, Blaeker, Hendrik, Dietmaier, Wolfgang, Dietel, Manfred, Hartmann, Arndt, Horn, Lars-Christian, Joehrens, Korinna, Kirchner, Thomas, Knuchel, Ruth, Mayr, Doris, Merkelbach-Bruse, Sabine, Schildhaus, Hans-Ulrich, Schirmacher, Peter, Tiemann, Markus, Tiemann, Katharina, Weichert, Wilko and Buettner, Reinhard (2021). MSI testing What is new? What should be considered? German version. Pathologe, 42 (4). S. 414 - 424. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1432-1963

Full text not available from this repository.

Abstract

Based on new trial data regarding immune checkpoint inhibitors (ICIs), the detection of high-grade microsatellite instability (MSI-H) or underlying deficient mismatch repair protein (dMMR) is now becoming increasingly important for predicting treatment response. For the first time, a PD-1 ICI (pembrolizumab) has been approved by the European Medicines Agency (EMA) for first-line treatment of advanced (stage IV) dMMR/MSI-H colorectal cancer (CRC). Further indications, such as dMMR/MSI-H endometrial carcinoma (EC), have already succeeded (Dostarlimab, 2nd line treatment) and others are expected to follow before the end of 2021. The question of optimal testing in routine diagnostics should therefore be re-evaluated. Based on a consideration of the strengths and weaknesses of the widely available methods (immunohistochemistry and PCR), a test algorithm is proposed that allows quality assured, reliable, and cost-effective dMMR/MSI-H testing. For CRC and EC, testing is therefore already possible at the primary diagnosis stage, in line with international recommendations (NICE, NCCN). The clinician is therefore enabled from the outset to consider not only the predictive but also the prognostic and predispositional implications of such a test when counseling patients and formulating treatment recommendations. As a basis for quality assurance, participation in interlaboratory comparisons and continuous documentation of results (e.g., QuIP Monitor) are strongly recommended.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Rueschoff, JosefUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Baretton, GustavoUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Blaeker, HendrikUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Dietmaier, WolfgangUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Dietel, ManfredUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hartmann, ArndtUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Horn, Lars-ChristianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Joehrens, KorinnaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kirchner, ThomasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Knuchel, RuthUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mayr, DorisUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Merkelbach-Bruse, SabineUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schildhaus, Hans-UlrichUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schirmacher, PeterUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Tiemann, MarkusUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Tiemann, KatharinaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Weichert, WilkoUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Buettner, ReinhardUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-603182
DOI: 10.1007/s00292-021-00944-7
Journal or Publication Title: Pathologe
Volume: 42
Number: 4
Page Range: S. 414 - 424
Date: 2021
Publisher: SPRINGER HEIDELBERG
Place of Publication: HEIDELBERG
ISSN: 1432-1963
Language: German
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
MISMATCH; IMMUNOHISTOCHEMISTRY; DIAGNOSIS; TUMORS; CARCINOMA; PROTEINMultiple languages
PathologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/60318

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item